Lexicon Pharmaceuticals Inc.

News & Events

Press Releases

In The Media

1. Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

   GlobeNewswire MAY 6, 2025 4:30 PM EDT
   THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXR...
   READ ARTICLE

2. Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

   GlobeNewswire MAY 6, 2025 8:00 AM EDT
   THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXR...
   READ ARTICLE

3. Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

   GlobeNewswire APR 2, 2025 8:00 AM EDT
   THE WOODLANDS, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: L...
   READ ARTICLE

4. Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

   GlobeNewswire MAR 28, 2025 7:30 AM EDT
   THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: L...
   READ ARTICLE

5. Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

   GlobeNewswire MAR 7, 2025 8:30 AM EST
   THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: L...
   READ ARTICLE

6. Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

   GlobeNewswire MAR 6, 2025 4:00 PM EST
   Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neurop...
   READ ARTICLE

7. Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

   GlobeNewswire MAR 4, 2025 4:15 PM EST
   THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: L...
   READ ARTICLE

8. Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

   GlobeNewswire MAR 3, 2025 7:00 AM EST
   Pilavapadin achieved meaningful pain reduction versus placebo and was well-tolerated in the 10 mg...
   READ ARTICLE

9. Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

   GlobeNewswire MAR 2, 2025 4:13 PM EST
   THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: L...
   READ ARTICLE

10. Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

    GlobeNewswire FEB 18, 2025 8:00 AM EST
    Data reinforce unique clinical advantages of sotagliflozin Published study is aligned...
    READ ARTICLE